These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33710617)

  • 21. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis.
    Sakisaka S; Koga H; Sasatomi K; Ohishi M; Kawaguchi T; Harada M; Taniguchi E; Uchimura Y; Ueno T; Sata M; Tanikawa K
    Liver; 2000 Feb; 20(1):78-87. PubMed ID: 10726964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
    Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
    Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis.
    Bossen L; Lau TS; Nielsen MB; Nielsen MC; Andersen AH; Ott P; Becker S; Glerup H; Svenningsen L; Eivindson M; Kornerup L; Kjeldsen NB; Neumann A; Møller HJ; Jepsen P; Grønbæk H
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
    Zhu H; Zheng M; He H; Lei H; Tai W; Yang J
    BMC Gastroenterol; 2023 Nov; 23(1):400. PubMed ID: 37978445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
    Kotb MA
    Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Primary Biliary Cholangitis including Transplantation.
    Muzahim Y; Wakil A; Bassi M; Pyrsopoulos N
    Clin Liver Dis; 2024 Feb; 28(1):103-114. PubMed ID: 37945152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis.
    Azemoto N; Abe M; Murata Y; Hiasa Y; Hamada M; Matsuura B; Onji M
    J Gastroenterol; 2009; 44(6):630-4. PubMed ID: 19370305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Barron-Millar B; Ogle L; Mells G; Flack S; Badrock J; Sandford R; Kirby J; Palmer J; Jopson L; Brain J; Smith GR; Rushton S; Hegade VS; Jones R; Rushbrook S; Thorburn D; Ryder S; Hirschfield G; ; Dyson JK; Jones DEJ
    Hepatology; 2021 Dec; 74(6):3269-3283. PubMed ID: 34129689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
    Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
    Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
    Ozaslan E; Efe C; Heurgué-Berlot A; Kav T; Masi C; Purnak T; Muratori L; Ustündag Y; Bresson-Hadni S; Thiéfin G; Schiano TD; Wahlin S; Muratori P
    Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of KSRP by miR-27b provides IFN-γ-induced post-transcriptional regulation of CX3CL1 in liver epithelial cells.
    Xia Z; Lu Y; Li X; Mao T; Chen XM; Zhou R
    Sci Rep; 2015 Dec; 5():17590. PubMed ID: 26631623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis.
    Nakano LA; Cançado ELR; Chaves CE; Madeira MCV; Katayose JT; Nabeshima MA; Fossaluza V; Uhrigshardt GG; Liting Z; Pinto VB; Carrilho FJ; Ono SK
    BMC Gastroenterol; 2020 Aug; 20(1):253. PubMed ID: 32758152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finding the cure for primary biliary cholangitis - Still waiting.
    Tanaka A; Gershwin ME
    Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
    Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
    Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study.
    Chang JI; Kim JH; Sinn DH; Cho JY; Kim KM; Oh JH; Park Y; Sohn W; Goh MJ; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2023 Jul; 17(4):620-628. PubMed ID: 36999383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM; Kaplan MM
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular Carcinoma in Primary Biliary Cholangitis.
    Sy AM; Ferreira RD; John BV
    Clin Liver Dis; 2022 Nov; 26(4):691-704. PubMed ID: 36270724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.